Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

doi:10.1200/JCO.2009.25.1496

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2010

Becker Heiko, Marcucci Guido, Maharry Kati, Radmacher Michael D, Mrózek Krzysztof, Margeson Dean, Whitman Susan P, Wu Yue-Zhong, Schwind Sebastian, Paschka Peter, Powell Bayard L, Carter Thomas H, Kolitz Jonathan E, Wetzler Meir, Carroll Andrew J, Baer Maria R, Caligiuri Michael A, Larson Richard A, Bloomfield Clara D

Abstract excerpt

PURPOSE: To analyze the prognostic significance of NPM1 mutations, and the associated gene- and microRNA-expression signatures in older patients with de novo, cytogenetically normal acute myeloid leukemia (CN-AML) treated with intensive chemotherapy. PATIENTS AND METHODS: One hundred forty-eight adults age >or= 60 years with de novo CN-AML, enrolled onto Cancer and Leukemia Group B protocols 9720 and 10201, were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCAAT-Enhancer-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Gene Expression Regulation, Leukemic

Share to Karyotyping

Share to Nucleophosmin

Share to Remission Induction

Share to Survival Rate

Share to WT1 Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 20026798
DOI: 10.1200/JCO.2009.25.1496
PMCID: PMC2815994

Genes

NPM1
BAALC
ERG
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.PMID 20026798Read ↗

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Semantic proximity Read ↗

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSemantic proximity Read ↗

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.Semantic proximity Read ↗

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.Semantic proximity Read ↗

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Semantic proximity Read ↗

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.Semantic proximity Read ↗

Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years.Semantic proximity Read ↗

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.Semantic proximity Read ↗

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Semantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.Semantic proximity Read ↗

Biological and clinical consequences of NPM1 mutations in AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.